HomeUP0 • FRA
add
Ultragenyx Pharmaceutical Inc
Previous close
€49.60
Day range
€50.00 - €50.00
Year range
€30.00 - €52.00
Market cap
5.15B USD
Avg Volume
4.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 147.03M | 35.75% |
Operating expense | 80.60M | -0.98% |
Net income | -131.60M | 17.66% |
Net profit margin | -89.51 | 39.34% |
Earnings per share | -1.52 | 32.44% |
EBITDA | -107.50M | 24.61% |
Effective tax rate | -0.66% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 763.82M | 38.38% |
Total assets | 1.62B | 23.42% |
Total liabilities | 1.19B | 0.32% |
Total equity | 432.42M | — |
Shares outstanding | 92.10M | — |
Price to book | 10.55 | — |
Return on assets | -19.89% | — |
Return on capital | -23.93% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -131.60M | 17.66% |
Cash from operations | -76.96M | 33.74% |
Cash from investing | 60.56M | -39.08% |
Cash from financing | 384.94M | 1,065.78% |
Net change in cash | 367.89M | 2,179.24% |
Free cash flow | -31.79M | 62.72% |
About
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
CEO
Founded
2010
Headquarters
Website
Employees
1,276